Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ambrx Biopharma Inc.AMAM · Entity 109604 | Director | May 18, 2023 | June 09, 2023 |
| ONCOLYTICS BIOTECH INCONCY · Entity 6721 | Director | June 01, 2026 | June 03, 2026 |
| PDS Biotechnology CorpPDSB · Entity 7939 | Director | January 12, 2026 | March 03, 2026 |
| ZyVersa Therapeutics, Inc.ZVSA · Entity 8639 | Director · Chief Executive Officer | July 11, 2025 | July 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ambrx Biopharma Inc.
Report date May 18, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 85,000 |
Reported balance
After 2023-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-07 · Grant · Acquired 85,000 · Balance 85,000 F1: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer. F2: Represents grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest as follows: on the earlier of (i) the one year anniversary of the date of grant and (ii) the day before the next annual general meeting. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2033-06-07 | Direct | 40,000 |
Reported balance
After 2023-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-07 · Grant · Acquired 40,000 · Balance 40,000 F3: The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the ADS. F4: The options vest on June 7, 2024. F1: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2033-05-18 | Direct | 17,500 |
Reported balance
After 2023-05-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-18 · Grant · Acquired 17,500 · Balance 17,500 F3: The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the ADS. F5: The options vested on June 6, 2023. F1: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer.
F2: Represents grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest as follows: on the earlier of (i) the one year anniversary of the date of grant and (ii) the day before the next annual general meeting.
F3: The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the ADS.
F4: The options vest on June 7, 2024.
F5: The options vested on June 6, 2023.
ONCOLYTICS BIOTECH INC
Report date June 01, 2026 · Filed June 03, 2026
This filing explicitly reported no securities owned.
PDS Biotechnology Corp
Report date January 12, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-01-12 | Direct | 54,876 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 54,876 · Balance 54,876 F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
ZyVersa Therapeutics, Inc.
Report date July 11, 2025 · Filed July 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2035-07-11 | Direct | 136,900 |
Reported balance
After 2025-07-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-11 · Grant · Acquired 136,900 · Balance 136,900 F1: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ambrx Biopharma, Inc.
Report date March 07, 2024 · Filed March 07, 2024
Section 16 reporting ended · disclosed 2024-03-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-07 · Disposition to issuer · Disposed 12,142 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock"). F4: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F3: These RSUs vest as follows: on the earlier of (i) the one year anniversary of the grant date of June 7, 2023, and (ii) the day before the next annual general meeting. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.79 · Expires 2033-05-18 | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F5: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest in thirty-six (36) equal monthly installments following May 19, 2023. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.79 · Expires 2033-05-18 | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-07 · Disposition to issuer · Disposed 2,500 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F7: These Company Options are fully vested and exercisable. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.72 · Expires 2033-06-07 | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-07 · Disposition to issuer · Disposed 5,714 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F8: The Company Common Stock subject to the Company Options vest on June 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J.
F2: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock").
F3: These RSUs vest as follows: on the earlier of (i) the one year anniversary of the grant date of June 7, 2023, and (ii) the day before the next annual general meeting.
F4: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU.
F5: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest in thirty-six (36) equal monthly installments following May 19, 2023.
F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration.
F7: These Company Options are fully vested and exercisable.
F8: The Company Common Stock subject to the Company Options vest on June 7, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:30 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | GrantStock Option · Derivative | 96,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001493152-26-027100 · ownership.xml · derivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Shares · 96,000 shares Expires 2036-06-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. F2 · derivative.exercise_date: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date. Read SEC document |
| January 12, 2026 Filed Mar 3, 2026 23:47 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 54,876 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001140361-26-007639 · form4.xml · derivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,876 Underlying: Common Stock · 54,876 shares Expires 2036-01-12 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 16:22 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options · Derivative | 136,900 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001641172-25-019725 · ownership.xml · derivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,900 Underlying: Common Stock · 136,900 shares Expires 2035-07-11 F1 · derivative.exercise_date: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 22:00 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,700 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001140361-25-022223 · form4.xml · derivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,700 Underlying: Common Stock · 22,700 shares Expires 2035-06-11 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:45 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Warrant · Derivative | 15,061 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001140361-25-006783 · form4.xml · derivative · entry 2 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,061 Underlying: Common Stock · 15,061 shares Expires 2030-02-28 F1 · price: The purchase price for the Common Warrant is included in the purchase price for the shares of Common Stock reflected in Table I above. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:45 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Stock | 15,061 | $1.66 | $25,001.26 |
DisclosureSEC source: 0001140361-25-006783 · form4.xml · nonDerivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,851 Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:05 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001140361-24-031293 · form4.xml · derivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:45 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerOption to Purchase Common Stock · Derivative | 5,714 | Not disclosed Strike: $13.72 | Not disclosed |
DisclosureSEC source: 0000950170-24-028188 · ownership.xml · derivative · entry 4 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,714 shares Expires 2033-06-07 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F8 · derivative.exercise_date: The Company Common Stock subject to the Company Options vest on June 7, 2024. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:45 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,500 | Not disclosed Strike: $13.79 | Not disclosed |
DisclosureSEC source: 0000950170-24-028188 · ownership.xml · derivative · entry 3 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2033-05-18 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F7 · derivative.exercise_date: These Company Options are fully vested and exercisable. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:45 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerOption to Purchase Common Stock · Derivative | 30,000 | Not disclosed Strike: $13.79 | Not disclosed |
DisclosureSEC source: 0000950170-24-028188 · ownership.xml · derivative · entry 2 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2033-05-18 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F5 · derivative.exercise_date: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest in thirty-six (36) equal monthly installments following May 19, 2023. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:45 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerRestricted Stock Units · Derivative | 12,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-028188 · ownership.xml · derivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,142 shares Expires not disclosed F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2 · derivative.exercise_price: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock"). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F3 · derivative.exercise_date: These RSUs vest as follows: on the earlier of (i) the one year anniversary of the grant date of June 7, 2023, and (ii) the day before the next annual general meeting. F3 · derivative.expiration_date: These RSUs vest as follows: on the earlier of (i) the one year anniversary of the grant date of June 7, 2023, and (ii) the day before the next annual general meeting. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 21:26 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001140361-23-034831 · form4.xml · derivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2033-07-14 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 16:17 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0000899243-23-015185 · doc4.xml · derivative · entry 2 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Ordinary Shares · 40,000 shares Expires 2033-06-07 F3 · derivative.exercise_price: The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the ADS. F4 · derivative.exercise_date: The options vest on June 7, 2024. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 16:17 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantOrdinary Shares | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015185 · doc4.xml · nonDerivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 F1 · security: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer. F2 · shares: Represents grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest as follows: on the earlier of (i) the one year anniversary of the date of grant and (ii) the day before the next annual general meeting. Read SEC document |
| May 24, 2023 Filed Jul 18, 2024 21:35 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options · Derivative | 1,627 | $0.00 Strike: $152.46 | $0.00 |
DisclosureSEC source: 0001493152-24-028404 · ownership.xml · derivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,627 Underlying: Common Stock · 1,627 shares Expires 2033-05-24 F1 · date: The option disclosed on this Form 4 was not previously reported due to an administrative oversight. F2 · shares: Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024. F3 · derivative.exercise_date: The option vests annually in three equal installments commencing on May 24, 2024. Read SEC document |
| May 18, 2023 Filed May 26, 2023 20:20 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantStock Option (right to buy) · Derivative | 210,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0000899243-23-013994 · doc4.xml · derivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Ordinary Shares · 210,000 shares Expires 2033-05-18 F1 · derivative.exercise_price: The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The Ordinary Shares subject to the option vest in thirty-six (36) equal monthly installments following May 19, 2023. F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven (7) Ordinary Shares of the Issuer. Read SEC document |
| May 18, 2023 Filed Jun 9, 2023 16:17 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0000899243-23-015185 · doc4.xml · derivative · entry 3 Glover Stephen C. · CIK 0001304406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Ordinary Shares · 17,500 shares Expires 2033-05-18 F3 · derivative.exercise_price: The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the ADS. F5 · derivative.exercise_date: The options vested on June 6, 2023. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantWarrant (right to buy) · Derivative | 1,750 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 14 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires 2027-12-12 F12 · price: The Reporting Person paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5. F11 · derivative.exercise_date: The warrant is immediately exercisable in full. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantWarrant (right to buy) · Derivative | 17,903 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 13 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 17,903 Underlying: Common Stock · 17,903 shares Expires 2023-10-31 F11 · derivative.exercise_date: The warrant is immediately exercisable in full. F2 · ownership.nature: The securities are held of record by Asclepius Life Sciences Fund, L.P ("ALS Fund"). Reporting Person serves as the managing member of ALS Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantWarrant (right to buy) · Derivative | 3,022 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 12 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,022 Underlying: Common Stock · 3,022 shares Expires 2023-10-31 F11 · derivative.exercise_date: The warrant is immediately exercisable in full. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantWarrant (right to buy) · Derivative | 70,881 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 11 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,881 Underlying: Common Stock · 70,881 shares Expires 2027-12-12 F11 · derivative.exercise_date: The warrant is immediately exercisable in full. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options (right to buy) · Derivative | 79,417 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 10 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,417 Underlying: Common Stock · 79,147 shares Expires 2032-02-03 F10 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on January 28, 2023. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options (right to buy) · Derivative | 126,138 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 9 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,138 Underlying: Common Stock · 126,138 shares Expires 2031-02-08 F9 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on February 8, 2022. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options (right to buy) · Derivative | 264,838 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 8 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,838 Underlying: Common Stock · 264,838 shares Expires 2029-04-02 F8 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options (right to buy) · Derivative | 168,761 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 7 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,761 Underlying: Common Stock · 168,761 shares Expires 2026-10-28 F7 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested on October 28, 2016. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options (right to buy) · Derivative | 138,980 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 6 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,980 Underlying: Common Stock · 138,980 shares Expires 2024-04-11 F6 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantSeries A Convertible Preferred Stock · Derivative | 18 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · derivative · entry 5 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires not disclosed F12 · price: The Reporting Person paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5. F5 · derivative.expiration_date: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantCommon Stock | 43,847 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · nonDerivative · entry 4 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 43,847 F1 · price: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer. F4 · ownership.nature: The securities are held of record by MedicaRx Inc. ("MRx"). Reporting Person serves as the managing director of MRx. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantCommon Stock | 49,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · nonDerivative · entry 3 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 49,636 F1 · price: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer. F3 · ownership.nature: The securities are held of record by Asclepius Master Fund, LTD. ("AM Fund"). Reporting Person serves as the managing director of AM Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantCommon Stock | 85,442 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · nonDerivative · entry 2 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 85,442 F1 · price: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer. F2 · ownership.nature: The securities are held of record by Asclepius Life Sciences Fund, L.P ("ALS Fund"). Reporting Person serves as the managing member of ALS Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:24 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantCommon Stock | 448,909 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-035479 · ownership.xml · nonDerivative · entry 1 Glover Stephen C. · CIK 0001304406 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,909 F1 · price: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 20:16 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001140361-22-024470 · form4.xml · derivative · entry 1 Glover Steve C · CIK 0001304406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 23:15 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001140361-21-021499 · form4.xml · derivative · entry 2 Glover Steve C · CIK 0001304406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-06-17 F2 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on June 17, 2022. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:15 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | PurchaseCommon Stock | 5,882 | $8.50 | $49,997.00 |
DisclosureSEC source: 0001140361-21-021499 · form4.xml · nonDerivative · entry 1 Glover Steve C · CIK 0001304406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,790 F1 · kind: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on June 17, 2021, and such shares of common stock are subject to a lock up agreement between the Reporting Person and Cantor Fitzgerald & Co., pursuant to which the shares cannot be sold for 90 days following June 15, 2021. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:57 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001140361-20-014781 · form4.xml · derivative · entry 1 Glover Steve C · CIK 0001304406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 23, 2023. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:30 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantCommon Stock | 38,400 | $1.30 | $49,920.00 |
DisclosureSEC source: 0001140361-20-003644 · form4.xml · nonDerivative · entry 1 Glover Steve C · CIK 0001304406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,908 F1 · kind: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on February 14, 2020. F2 · balance_after: Represents 19,508 shares of common stock previously issued to the Reporting Person. The Reporting Person was a former stockholder of privately held PDS Biotechnology Corporation, a Delaware corporation ("Private PDS"). The Reporting Person received such shares of Issuer in exchange for the shares of common stock the Reporting Person formerly held in Private PDS in connection with the previously disclosed business combination with Private PDS, which was consummated on March 15, 2019. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 20:50 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0001127602-19-023251 · form4.xml · derivative · entry 1 Glover Steve C · CIK 0001304406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-28 F1 · derivative.exercise_date: One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 28, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.